leadf
logo-loader
viewOpen Orphan PLC

Open Orphan unit says wins two-year contract with tier-one German pharma company

"This new contract further demonstrates Open Orphan's ability to execute on its significant pipeline of contracts with major pharmaceutical business," said chairman Cathal Friel

Open Orphan PLC -

Open Orphan PLC (LON:ORPH) said its Venn Life Sciences arm has won a two-year contract with a ‘tier-one’ German pharmaceutical company.

The new agreement is an extension of work already being undertaken and will see Venn deliver further analytical services.

These services will include pharmacometrics (using maths, statistics and the sciences to model the interaction of drugs in the body) and pharmacokinetics, a branch of pharmacology that assesses how a drug is absorbed and distributed by the body.

As the latter is becoming an e important part of regulatory submissions, Open Orphan said the Venn team in Breda, in the Netherlands, is “increasing its specialisation with the ambition of becoming the European leader in pharmacometric analysis”.

"Open Orphan's subsidiaries continue to excel, highlighting the well-rounded expertise of the group and in turn maximising shareholder value. This contract delivers on a number of our ambitions, it is a large multi-year contract generating recurring revenues, it is with a large partner and it utilises our expertise in pharmacometric analysis,” said Open Orphan chairman Cathal Friel in a statement.

"This new contract further demonstrates Open Orphan's ability to execute on its significant pipeline of contracts with major pharmaceutical business. It also demonstrates Venn Life Sciences position as a market leader in its field."

Quick facts: Open Orphan PLC

Price: 25.2 GBX

AIM:ORPH
Market: AIM
Market Cap: £168.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan first half: 'period of integration, restructuring and setting...

Proactive Analyst Emma Ulker talks through how Open Orphan (LON:ORPH) performed in the first half of the year.  In the six-month period to June 2020, the company focused on integration and restructuring following its acquisition of lab services and challenge studies specialist hVIVO in...

on 09/30/2020

2 min read